易患黑色素瘤家族中黑色素瘤及其他癌症风险的四十年随访研究
自1976年起在美国国家癌症研究所对56个易患黑色素瘤家族(29个突变阳性、27个突变阴性)的1226名成员随访至多4年,与监测、流行病学和最终结果计划的人群发病率比较。首次检查后黑色素瘤风险约为首次检查前的三分之一(突变阳性与阴性家族均如此),黑色素瘤患者发生第二原发黑色素瘤的风险增加10倍,突变阳性家族中黑色素瘤后胰腺癌风险仅见升高。
要点
- 首次检查后黑色素瘤风险约为首次检查前的三分之一,突变阳性与阴性家族均如此。
- 黑色素瘤患者发生第二黑色素瘤的风险增加10倍,突变阳性家族中略高。
- 突变阳性家族中黑色素瘤后仅胰腺癌风险升高,其他第二癌症风险未升高。
核心结论
- 在4个十年随访中,突变阳性与突变阴性家族的黑色素瘤前瞻性风险均大幅下降,而一般人群中黑色素瘤大幅增加。
研究设计与样本
- 自1976年起在美国国家癌症研究所对56个易患黑色素瘤家族(29个突变阳性、27个突变阴性)的1226名成员随访至多4年,并与监测、流行病学和最终结果计划的人群发病率比较。
- 所有家族均检测CDKN2A与CDK4突变。
主要发现
- 按研究的三个日历时期比较,第一原发黑色素瘤风险略有下降。
- 首次检查后黑色素瘤风险约为首次检查前的三分之一,突变阳性与突变阴性家族均如此。
- 黑色素瘤患者中,第二黑色素瘤风险在所有家族中增加10倍,突变阳性家族中略高。
- 突变阳性家族中黑色素瘤后仅胰腺癌风险升高,其他第二癌症风险未见升高。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: Since 1976, melanoma-prone families have been followed at the National Cancer Institute to identify etiologic factors for melanoma. We compared risks of melanoma and other cancers in 1,226 members of 56 families followed for up to 4 decades with population rates in the Surveillance, Epidemiology, and End Results program. All families were tested for mutations in CDKN2A and CDK4; 29 were mutation-positive and 27 mutation-negative. We compared rates of invasive melanomas, both first and second, by family mutation status, with Surveillance, Epidemiology, and End Results program. Comparing three calendar periods of the study, risk of first primary melanoma decreased slightly. Risks of melanoma after first examination, however, were approximately one-third the risks prior to the first examination in both mutation-positive and mutation-negative families. Among patients with melanoma, risk of a second melanoma was increased 10-fold in all families; risk was somewhat higher in mutation-positive families. Risks of other second cancers were increased only for pancreatic cancer after melanoma in mutation-positive families. Over 4 decades, prospective risk of melanoma has decreased substantially in both mutation-positive and mutation-negative families, when melanoma has greatly increased in the general population. TRIAL REGISTRATION: NCI 02-C-0211, ClinicalTrials.gov ID NCT00040352.
引用
- Tucker MA, Elder DE, Curry M, et al. Risks of Melanoma and Other Cancers in Melanoma-Prone Families over 4 Decades. J Invest Dermatol. 2018. PMID: 29408205. doi:10.1016/j.jid.2018.01.021
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。